What Estalis Sequidot Treats: Main Uses and Benefits

This therapy is commonly used to provide supportive relief for symptoms related to systemic imbalance and physical discomfort caused by estrogen deficiency after menopause. As a combined sequential Hormone Replacement Therapy (HRT), it is generally considered relevant in conditions presenting with acute or unstable symptom patterns in women who retain their uterus.

The medicine is used for the short-term treatment of symptoms of estrogen deficiency in menopausal women who have an intact uterus, and for the prevention of postmenopausal bone mineral density loss in women at high risk of fracture who are intolerant of other treatments.

The main therapeutic uses involve addressing symptom clusters that may become intense or disruptive, including symptoms related to systemic imbalance (hot flushes and night sweats), symptoms related to inflammatory or irritative states (vaginal dryness and dyspareunia), and long-term issues like the prevention of osteoporosis.

“This symptomatic relief contributes to improved comfort during periods when these symptoms would otherwise create noticeable interference with daily stability.”

It is applied across domains where additional symptomatic support is needed, assisting with symptom clusters that interfere with daily comfort. The sequential design contributes to improved comfort by offering endometrial protection, which is relevant for the patient group with an intact uterus.

---

Quick Fact: Symptomatic Domains and Benefits

Symptom Domain	Key Therapeutic Benefit
Vasomotor Symptoms	Assists with easing the overall symptom load of hot flushes and night sweats.
Urogenital Atrophy	Contributes to improved comfort by managing vaginal dryness and dyspareunia.
Bone Health	May provide prophylactic support relevant for high-risk women.

Who can and cannot use Estalis Sequidot?

This eligibility profile is defined by official regulatory bodies and is based strictly on the risk profile of combined hormone replacement therapy (HRT).

Classification	Eligibility Status (Official Labeling)
Eligible Population	Postmenopausal women who have an intact uterus.
Contraindicated	Women with a history of breast cancer, any known estrogen-dependent cancer, or undiagnosed abnormal genital bleeding.
Contraindicated	Patients with current or history of blood clots (DVT/PE), stroke, heart attack, or known thrombophilic disorders.
Contraindicated	Patients with acute liver disease or the blood disorder Porphyria.
Not Recommended	Women who are pregnant (contraindicated) or breastfeeding.

---

Eligibility and Age Restrictions

Estalis Sequidot is not indicated in children or adolescents, as safety and effectiveness have not been established in the pediatric population. Use in women 65 years of age or older is limited; caution is advised due to the documented increase in the risk of probable dementia and other serious vascular events in this age group.

Conditional Use

Use requires close supervision and specialized monitoring for patients with pre-existing conditions that may be aggravated, such as hypertriglyceridemia (high blood fats), asthma, epilepsy, migraine, and certain hepatic or renal impairments.

The official regulatory profile for Estalis Sequidot identifies interaction patterns rooted in specific pharmacokinetic and co-administration constraints. The most significant interactions occur with medicines that modulate the CYP3A4 enzyme system.

Co-administration with enzyme inducers, such as Rifampicin, Carbamazepine, Phenytoin, Barbiturates, or the herbal product St. John's wort, is documented to accelerate hormone clearance, resulting in reduced plasma concentrations of both estradiol and norethisterone. Conversely, enzyme inhibitors like Ketoconazole and certain anti-infective agents (e.g., Ritonavir, Nelfinavir) may increase the plasma concentrations of the active ingredients.

Interaction Classification	Documented Constraint
Contraindicated Combinations	Co-administration is formally prohibited with combination drug regimens containing Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir due to the documented risk of severe transaminase elevations.
Substance/Lab Interference	Acute alcohol ingestion may lead to a documented elevation in circulating estradiol levels. Therapy may also formally affect the results of specific diagnostic assessments, including thyroid function tests and glucose tolerance tests.

Estalis Sequidot delivers estradiol and norethisterone acetate (NETA) transdermally. Estradiol functions as an estrogen receptor agonist, binding to and activating the intracellular Estrogen Receptors ( ERalpha and ERbeta). This ligand-receptor complex subsequently dimerizes and translocates to the cell nucleus, where it modulates the transcription of target genes by binding to Estrogen Response Elements (EREs) in the promoter regions. The resulting cascade of gene expression modification governs protein synthesis in target tissues, notably influencing the neuroendocrine, skeletal, and vascular systems.

Norethisterone acetate is a prodrug rapidly hydrolyzed to the active compound, norethisterone (NET). NET acts as a progesterone receptor (PR) agonist, binding to the Progesterone Receptor and inducing a conformational change. The activated PR complex regulates gene expression, primarily exerting anti-proliferative effects on the endometrium, counteracting the estrogen-mediated stimulation of endometrial cell proliferation.

Estalis Sequidot is a sequential combined transdermal system intended solely for application to the skin, which is the approved route of administration. The regimen is structured as a 28-day continuous sequential cycle, which alternates between an estrogen-only phase (Days 1–14) and a combined estrogen/progestogen phase (Days 15–28).

The dosing frequency is twice weekly, meaning a new patch must be applied every 3 to 4 days, always on the same two days of the week to maintain a continuous hormonal schedule. The principle for treatment duration is the use of the lowest effective dose for the shortest duration consistent with the necessary clinical objectives. Available strengths for the combined phase deliver 50 mcg of estradiol per day with either 140 mcg or 250 mcg of Norethisterone acetate per day.

Procedural instructions mandate that the patch must be placed on a clean, dry area of the abdomen or buttocks; it is explicitly stated that the patch must never be applied on or near the breasts. Application sites must be rotated consistently, requiring at least a one-week interval before a patch is applied to the exact same skin location. If a patch change is missed, a new patch should be applied as soon as possible, and the original treatment schedule must be maintained thereafter. Use is not indicated in children.

Research evidence / Overview of Studies for Estalis Sequidot

1. Evidence for Use in Vasomotor and Systemic Symptoms

The research base includes Randomized Controlled Trials (RCTs) that explored how symptoms like hot flushes and night sweats were measured in relation to the transdermal patch. These studies was evaluated in populations of postmenopausal women with an intact uterus. Findings describe patterns observed in the studies, with research reporting changes measured during the short-term study period. However, long-term VMS outcomes with this combination remain insufficiently studied in large-scale RCTs, and comparative evidence is lacking versus other systemic hormone delivery methods.

2. Evidence for Endometrial Status Monitoring

For women with an intact uterus, sequential administration requires specific research. Studies was evaluated in these populations, where research examined a critical component: the status of the uterine lining (endometrium). Study outcomes examined included the incidence of unscheduled bleeding or spotting and patterns observed related to the status of the uterine lining upon histological assessment. The studies reported outcomes reflecting a planned and monitored response of the endometrium, which is consistently evaluated for this type of therapy.

3. Evidence for Bone Mineral Density Changes

This section reviews intermediate-term clinical trials and Systematic Reviews used to examine patterns related to Bone Mineral Density (BMD). The therapy was studied for women at high risk of fracture. Findings describe patterns observed in the studies where measurements of BMD at key skeletal sites research highlights changes measured during the study period. The results apply only to the populations studied, and long-term effects are not fully established regarding fracture reduction, as this evidence is often derived from synthesizing data across general HRT studies.

4. What Is Still Uncertain About the Research Base

Key research gaps include the limited follow-up duration in many primary efficacy studies, meaning certainty remains low for outcomes extending beyond one to two years. Comparative evidence is lacking from dedicated, large-scale studies directly comparing the symptomatic and long-term effects of this transdermal patch against other systemic hormone delivery methods. Furthermore, data for certain groups remain insufficient for populations such as women many years postmenopausal or those with specific chronic comorbidities.

Key Studies & References

1. Therapeutic Goods Administration (TGA) Australian Register of Therapeutic Goods (ARTG) - Estalis Sequi

Common questions about Estalis Sequidot (FAQ)

---

Q: What is the main difference between Estalis Sequidot and other hormone patches?

Official drug classifications describe Estalis Sequidot as a sequential combined transdermal system. The combined aspect means it delivers two hormones, estradiol and norethisterone acetate, rather than just one. The sequential aspect refers to the specific monthly cycle, which alternates between an estrogen-only patch phase and a combined hormone phase.

---

Q: Do people typically use Estalis Sequidot for night sweats?

The main approved use, according to regulatory documents, is to address the systemic causes of symptoms occurring after menopause. This often includes vasomotor symptoms like hot flushes and sleeping problems associated with night sweats. Clinical studies have examined the measured effect of the patch on these specific symptoms.

---

Q: How quickly do the hormones from the patch enter the bloodstream?

The patch is known as a transdermal system, meaning the hormones are absorbed directly through the skin into the bloodstream. This system is designed to provide a sustained release over the scheduled wear time. Specific figures on the timing of absorption are detailed in the full product information.

---

Q: What does 'Sequidot' refer to in the drug name?

The name 'Sequidot' refers to the sequential nature of the patch regimen. The pack contains two different-shaped patches—a Phase I (estrogen-only) and a Phase II (estrogen and progestogen) patch—which are worn sequentially during the 28-day cycle.

---

Q: Are there specific vitamins or supplements that should not be taken with Estalis Sequidot?

Official prescribing information notes an interaction with the herbal product St. John's wort, which can reduce the levels of the active ingredients in the bloodstream. Information regarding non-prescription supplements and potential interactions is best reviewed with a healthcare professional.

---

Q: Is alcohol consumption restricted while using the Estalis Sequidot patch?

Regulatory prescribing information states that acute alcohol ingestion may lead to a documented elevation in circulating estradiol levels. Understanding this risk involves reviewing individual alcohol consumption patterns with a healthcare professional.

---

Q: What research exists about the effect of Estalis Sequidot on cholesterol levels?

Clinical documentation for systemic Hormone Replacement Therapy (HRT) generally confirms that combined estrogen-progestogen therapy can influence plasma lipoprotein and cholesterol levels. The specific effects of this product on these measurements are described in the full clinical data summaries.

---

Q: Is it true that Estalis Sequidot is primarily used for menopausal symptoms?

Yes, the fundamental purpose and official indication for this medicine is the relief of symptoms occurring after menopause. Official bodies state the use is intended only when symptoms are considered moderate to severe and significantly impact a woman's quality of life.

---

Q: Is Estalis Sequidot approved for preventing bone loss (osteoporosis)?

Official regulatory documents list the prevention of osteoporosis as an approved use for this product. The regulatory labeling specifies this indication for use in postmenopausal women at an increased risk of fractures where other medications are not considered suitable.

---

Q: Do studies suggest that Estalis Sequidot helps with mood swings?

The official adverse event profile lists persistent sad mood as a possible side effect, but the primary studies focus on physical symptoms like hot flushes. Any effect on mood should be reviewed with a healthcare professional.

---

Q: What is the expected timeline for a patient to start feeling benefits?

Clinical trials that measured effectiveness for vasomotor symptoms, such as hot flushes, typically measured outcomes at Week 4 and Week 12 of treatment. Individual results may vary, but these timelines provide a general expectation based on research.

---

Q: Are there any official reports of Estalis Sequidot causing allergic skin reactions?

Yes, regulatory warnings include information on the possibility of a severe allergic reaction to occur, such as hives or swelling of the face or throat. This risk is separate from the very common but milder Application Site Reactions, such as redness or itching.

---

Q: Can I wear the patch during an X-ray or MRI scan?

Regulatory safety warnings advise that some transdermal patches contain metal components which may overheat during an MRI scan and cause skin burns. Official safety information notes that the MRI facility and the patient's doctor should be informed about any patch being worn before the scan.

---

Q: Is there a maximum age limit for starting Estalis Sequidot?

Official guidance on Hormone Replacement Therapy notes that the risk of serious complications increases if treatment is started at age 60 or older or more than 10 years after menopause. The decision to start treatment is typically determined by a healthcare professional based on a detailed review of an individual's health profile and risk factors.

---

Q: Can the patch be cut into smaller pieces if someone is sensitive to the dose?

No. The patch is designed as a specific dose-delivery system and is not intended to be cut or altered in any way. Official instructions confirm that the patch must be applied to the skin intact.

---

Q: What ingredients are used in the adhesive of the patch?

The full official labeling includes a detailed list of all non-medicinal ingredients (excipients) used in the patch's construction, which includes the adhesive components. These details are typically provided to allow patients to check for any known allergies.

---

Q: Can the use of Estalis Sequidot affect fertility?

Estalis Sequidot is intended for postmenopausal women and its use is strictly contraindicated during pregnancy. The medication is not approved or intended for use in women of reproductive age.

---

Q: Can Estalis Sequidot affect the results of a blood test?

Official regulatory information states that the use of Estalis Sequidot may formally affect the results of certain laboratory diagnostic assessments. Specifically mentioned tests include those for thyroid function and glucose tolerance tests.

---

Q: Is it necessary to use a moisturizer before applying the patch?

No. Official patient information states that using products like skin moisturizers or creams on the application site immediately before applying the patch may interfere with the patch's adherence to the skin.

---

Q: Does Estalis Sequidot interact with grapefruit juice?

Grapefruit and grapefruit juice contain compounds that can inhibit the CYP3A4 enzyme system in the liver, which is responsible for breaking down the hormone estradiol. Official information highlights that this action may lead to increased hormone levels in the body.

---

Q: Do people who have migraines have specific warnings about using Estalis Sequidot?

Yes. Migraine is listed as a pre-existing condition for which the use of HRT involves close supervision and monitoring. Furthermore, a sudden, severe headache or the worsening of a migraine is listed as a serious side effect that requires prompt medical attention.

---

Q: Can the patch be worn while swimming or showering?

The patch is designed for continuous wear, but official patient information states that its adherence can be compromised. Specifically, the use of bath oils or soaps with a high cream content could cause the patch to fall off. The patch should adhere best when applied to clean, dry, intact skin.

---

The storage and disposal of Estalis SequiDot must comply with official regulatory labeling to ensure product stability and safety.

Storage Conditions

The transdermal systems can be stored at room temperature, defined as 20 C to 25 C. Alternatively, unopened boxes may be kept refrigerated at 2 C to 8 C, but the product must not be frozen. The patches must be protected from direct heat, sunlight, and moisture; they should be kept in the original sealed pouch and carton until immediately before use.

Handling Constraint	Requirement
Temperature Rule	Must not be frozen.
Stability Check	Do not use after the expiry date.
Child Safety	Keep all patches (used and unused) out of the reach of children and pets.

Disposal Instructions

Used patches must be immediately folded in half so the sticky side adheres to itself. The folded patches must be disposed of in a sturdy container placed in the household trash, ensuring they remain inaccessible to children and pets. Do not flush patches down the toilet; unused or expired medicine should be returned to a pharmacist for appropriate pharmaceutical waste disposal.